Cardiovascular Safety of COX-2 Inhibition: Time to Inform Systems of Postmarketing Surveillance?

Therapy
doi 10.2217/14750708.2.3.325
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Cardiovascular Risk and COX-2 Inhibition in Rheumatological Practice

Journal of Human Hypertension
Internal Medicine
2004English

Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan

Journal of Rheumatology
RheumatologyAllergyImmunology
2009English

Viscum Album-Mediated COX-2 Inhibition Implicates Destabilization of COX-2 mRNA

PLoS ONE
Multidisciplinary
2015English

Postmarketing Surveillance of Adverse Drug Reactions

BMJ
1984English

Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients With Rheumatoid Arthritis in Japan

Journal of Rheumatology
RheumatologyAllergyImmunology
2013English

Postmarketing Surveillance Study of Permethrin Creme Rinse.

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1992English

FDA Will Increase Postmarketing Surveillance of Drugs

BMJ
2004English

TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance Study

Clinical Colorectal Cancer
OncologyGastroenterology
2016English

Inhibition of Cyclooxygenase 2 (COX-2) Alters Cerebral Vasoreactivity to Endothelin-1 (Et-1) Administration

Pediatric Research
Child HealthPediatricsPerinatology
1999English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy